gefitinib has been researched along with stattic in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (stattic) | Trials (stattic) | Recent Studies (post-2010) (stattic) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 142 | 0 | 130 |
| Protein | Taxonomy | gefitinib (IC50) | stattic (IC50) |
|---|---|---|---|
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | 5.1 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.043 | |
| Thioredoxin glutathione reductase | Schistosoma mansoni | 2.01 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Z; Lan, W; Lin, J; Shen, R; Wang, S; Wang, X; Wang, Y; Wei, H; Zhong, G | 1 |
1 other study(ies) available for gefitinib and stattic
| Article | Year |
|---|---|
Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic S-Oxides; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-6; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Protein Kinase Inhibitors; STAT3 Transcription Factor; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2021 |